نتایج جستجو برای: deferiprone

تعداد نتایج: 447  

Journal: :international journal of pediatrics 0
sasan hejazi department of pediatrics, faculty of medicine, urmia university of medical sciences, urmia, iran. omid safari department of pediatrics, faculty of medicine, alborz university of medical sciences, karaj, iran. reza arjmand department of pediatrics, faculty of medicine, alborz university of medical sciences, karaj, iran. mostafa qorbani department of community medicine, faculty of medicine, alborz university of medical sciences, karaj, iran. kumars pourrostami department of pediatrics, faculty of medicine, alborz university of medical sciences, karaj, iran. abdolmohammad safari department of psychology, ilam branch, islamic azad university, ilam, iran.

background: patients with transfusional iron overload have depended on iron chelation therapy and improving chelation regimens have been of the highest priority. the aim of this study was to compare effect of combined versus monotherapy with deferoxamine (dfo) and deferiprone (dfp) in iron overloaded beta thalassemia (bt) major patients materials and methods we studied 36 bt major patients (mea...

Journal: :AJNR. American journal of neuroradiology 2011
M Levy R H Llinas

A man with superficial siderosis showed improvement in symptoms and reduction in hemosiderin by MR imaging following treatment with deferiprone, a lipid-soluble iron chelator.

2002
Ian R. Wanless George Sweeney Amar P. Dhillon Maria Guido Antonio Piga Renzo Galanello M. Rita Gamberini Elias Schwartz Alan R. Cohen

Patients with thalassemia major require lifelong chelation therapy to prevent ironinduced organ damage. The orally active chelator deferiprone has been proposed as an alternative for patients unable or unwilling to use deferoxamine. One report has concluded that deferiprone may worsen hepatic fibrosis in patients with thalassemia, whereas others have found no detrimental effect. A panel of 3 pa...

2016
Fernando Tricta Jack Uetrecht Renzo Galanello John Connelly Anna Rozova Michael Spino Jan Palmblad

Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC). Here, we analyze all episodes of agranulocytosis (n = 161) and neutropenia (n = 250) during deferiprone use in clinical trials (CT) and postmarketing surveillance programs (PMSP). Rates of agranulocy...

2013
Hartmut M. Hanauske-Abel Deepti Saxena Paul E. Palumbo Axel-Rainer Hanauske Augusto D. Luchessi Tavane D. Cambiaghi Mainul Hoque Michael Spino Darlene D'Alliessi Gandolfi Debra S. Heller Sukhwinder Singh Myung Hee Park Bernadette M. Cracchiolo Fernando Tricta John Connelly Anthony M. Popowicz Richard A. Cone Bart Holland Tsafi Pe’ery Michael B. Mathews

HIV-1 blocks apoptosis, programmed cell death, an innate defense of cells against viral invasion. However, apoptosis can be selectively reactivated in HIV-infected cells by chemical agents that interfere with HIV-1 gene expression. We studied two globally used medicines, the topical antifungal ciclopirox and the iron chelator deferiprone, for their effect on apoptosis in HIV-infected H9 cells a...

2015
Chhanda Bose Judit K. Megyesi Sudhir V. Shah Kim M. Hiatt Kimberly A. Hall Oleg Karaduta Sundararaman Swaminathan Pavel Strnad

Nephrogenic systemic fibrosis is associated with gadolinium contrast exposure in patients with reduced kidney function and carries high morbidity and mortality. We have previously demonstrated that gadolinium contrast agents induce in vivo systemic iron mobilization and in vitro differentiation of peripheral blood mononuclear cells into ferroportin (iron exporter)-expressing fibrocytic cells. I...

2016
Deepti Saxena Michael Spino Fernando Tricta John Connelly Bernadette M. Cracchiolo Axel-Rainer Hanauske Darlene D’Alliessi Gandolfi Michael B. Mathews Jonathan Karn Bart Holland Myung Hee Park Tsafi Pe’ery Paul E. Palumbo Hartmut M. Hanauske-Abel

UNLABELLED Antiretrovirals suppress HIV-1 production yet spare the sites of HIV-1 production, the HIV-1 DNA-harboring cells that evade immune detection and enable viral resistance on-drug and viral rebound off-drug. Therapeutic ablation of pathogenic cells markedly improves the outcome of many diseases. We extend this strategy to HIV-1 infection. Using drug-based lead discovery, we report the c...

2012
Francisco Alpendurada Gill C Smith John-Paul Carpenter Sunil V Nair Mark A Tanner Winston Banya Carlo Dessi Renzo Galanello John Malcolm Walker Dudley J Pennell

BACKGROUND Combination therapy with deferoxamine and oral deferiprone is superior to deferoxamine alone in removing cardiac iron and improving left ventricular ejection fraction (LVEF). The right ventricle (RV) is also affected by the toxic effects of iron and may cause additional cardiovascular perturbation. We assessed the effects of combination therapy on the RV in thalassaemia major (TM) us...

Journal: :JPMA. The Journal of the Pakistan Medical Association 2009
Raihan Sajid Farooq Ghani Salman Adil Mohammad Khurshid

OBJECTIVE To determine the efficacy and adverse effects of deferiprone in patients with Thalassemia Major. METHODS A prospective case series study was conducted at the Fatimid Foundation Blood Bank and Haematological Diseases center Lahore. A total of 87 patients entered into the study between September 2005 and November 2006. Deferiprone was given at subsidized rates at a dose of 75/mg/day f...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید